Home › Cancro (tutti i tipi) › Indiana › Indianapolis
Studi clinici su Cancro (tutti i tipi) a Indianapolis, IN
24 studi su Cancro (tutti i tipi) cercano partecipanti presso sedi a Indianapolis e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Daily Hand-Held Vibration Therapy
In reclutamento
- Indiana University Melvin & Bren Simon Cancer Center, Indianapolis
- IU Health Joe & Shelly Schwarz Cancer Center, Indianapolis
- Indiana University Health West, Avon · a 13 mi di distanza
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
In reclutamentoStudio osservazionale
- Indiana University, Indianapolis
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
In reclutamentoFase 3
- Franciscan Health Oncology and Hematology Specialists, Indianapolis
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
In reclutamentoFase 3
- Franciscan St. Francis Health /ID# 279788, Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
In reclutamentoFase 1/2
- Community Health Network, Indianapolis
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
In reclutamentoFase 2
- Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
In reclutamentoFase 2/3
- IN Univ Simon Cancer Center, Indianapolis
- Franciscan Health Indianapolis, Indianapolis
Collection of Tissue Samples for Cancer Research
In reclutamentoStudio osservazionale
- Indiana University - Purdue, Indianapolis
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
In reclutamentoFase 3
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
- Community Cancer Center North, Indianapolis
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
In reclutamentoFase 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Project: Every Child for Younger Patients With Cancer
In reclutamentoStudio osservazionale
- Riley Hospital for Children, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
Abatacept in Immune Checkpoint Inhibitor Myocarditis
In reclutamentoFase 3
- Franciscan Health, Indianapolis
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
In reclutamentoFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
- e altri 1
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
In reclutamentoFase 1
- Franciscan St. Francis Health /ID# 280928, Indianapolis
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
In reclutamentoFase 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
In reclutamentoVolontari sani benvenuti
- Indiana University School of Medicine, Indianapolis
Childhood Cancer Survivor Study
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Indiana University/Riley Hospital for Children, Indianapolis
Galleri® in the Medicare Population.
In reclutamentoVolontari sani benvenuti
- Community Health Network East, Indianapolis
- Community Health Network South, Indianapolis
The Food Environment, Microbial Cysteine Metabolism, and Cancer Disparities
In reclutamento
- University Hospital Clinical Research Center, Indianapolis
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
In reclutamento
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
GEMINI-NSCLC: NSCLC Biomarker Study
In reclutamentoStudio osservazionale
- Community Health Network, Indianapolis
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- IU Simon Comprehensive Cancer Center, Indianapolis
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
In reclutamentoFase 1/2
- Community Health Network, Inc., Indianapolis
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
In reclutamento
- Indiana University - Melvin and Bren Simon Cancer Center, Indianapolis
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Franciscan Health Indianapolis, Indianapolis
Studi su Cancro (tutti i tipi) in altre città
- Houston, TX121 studi
- New York City, NY110 studi
- Boston, MA86 studi
- Los Angeles, CA73 studi
- Nashville, TN65 studi
- Philadelphia, PA59 studi
- Durham, NC58 studi
- Washington, DC58 studi
- Chicago, IL51 studi
- Seattle, WA49 studi
- Atlanta, GA49 studi
- Arlington, VA48 studi
Altri studi a Indianapolis
- Cancro del polmone non a piccole cellule32 studi
- Insufficienza cardiaca23 studi
- Cancro al seno20 studi
- Obesità20 studi
- Cancro metastatico19 studi
- Cancro colorettale18 studi
- Cancro ovarico17 studi
- Cancro ai polmoni16 studi
- Malattie cardiovascolari16 studi
- Diabete di tipo 114 studi
- Cancro dell'endometrio14 studi
- Morbo di Alzheimer14 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.